182 related articles for article (PubMed ID: 22697346)
1. Can correcting the ΔF508-CFTR proteostasis-defect rescue CF lung disease?
Valle CW; Vij N
Curr Mol Med; 2012 Aug; 12(7):860-71. PubMed ID: 22697346
[TBL] [Abstract][Full Text] [Related]
2. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
3. Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.
Belcher CN; Vij N
Curr Mol Med; 2010 Feb; 10(1):82-94. PubMed ID: 20205681
[TBL] [Abstract][Full Text] [Related]
4. Tgf-β1 inhibits Cftr biogenesis and prevents functional rescue of ΔF508-Cftr in primary differentiated human bronchial epithelial cells.
Snodgrass SM; Cihil KM; Cornuet PK; Myerburg MM; Swiatecka-Urban A
PLoS One; 2013; 8(5):e63167. PubMed ID: 23671668
[TBL] [Abstract][Full Text] [Related]
5. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.
Van Goor F; Straley KS; Cao D; González J; Hadida S; Hazlewood A; Joubran J; Knapp T; Makings LR; Miller M; Neuberger T; Olson E; Panchenko V; Rader J; Singh A; Stack JH; Tung R; Grootenhuis PD; Negulescu P
Am J Physiol Lung Cell Mol Physiol; 2006 Jun; 290(6):L1117-30. PubMed ID: 16443646
[TBL] [Abstract][Full Text] [Related]
6. Aggregates of mutant CFTR fragments in airway epithelial cells of CF lungs: new pathologic observations.
Du K; Karp PH; Ackerley C; Zabner J; Keshavjee S; Cutz E; Yeger H
J Cyst Fibros; 2015 Mar; 14(2):182-93. PubMed ID: 25453871
[TBL] [Abstract][Full Text] [Related]
7. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR).
Caohuy H; Yang Q; Eudy Y; Ha TA; Xu AE; Glover M; Frizzell RA; Jozwik C; Pollard HB
J Biol Chem; 2014 Dec; 289(52):35953-68. PubMed ID: 25384981
[TBL] [Abstract][Full Text] [Related]
8. Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR.
Villella VR; Esposito S; Maiuri MC; Raia V; Kroemer G; Maiuri L
Autophagy; 2013 Sep; 9(9):1431-4. PubMed ID: 23800975
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis.
Dormer RL; Harris CM; Clark Z; Pereira MM; Doull IJ; Norez C; Becq F; McPherson MA
Thorax; 2005 Jan; 60(1):55-9. PubMed ID: 15618584
[TBL] [Abstract][Full Text] [Related]
10. CFTR: cystic fibrosis and beyond.
Mall MA; Hartl D
Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
[TBL] [Abstract][Full Text] [Related]
11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
12. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
Elife; 2015 Dec; 4():. PubMed ID: 26701908
[TBL] [Abstract][Full Text] [Related]
13. SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis.
Grubb BR; Gabriel SE; Mengos A; Gentzsch M; Randell SH; Van Heeckeren AM; Knowles MR; Drumm ML; Riordan JR; Boucher RC
Am J Respir Cell Mol Biol; 2006 Mar; 34(3):355-63. PubMed ID: 16284361
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.
Roomans GM
Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of the ion transport defect in cystic fibrosis.
Roomans GM
Expert Opin Investig Drugs; 2001 Jan; 10(1):1-19. PubMed ID: 11116277
[TBL] [Abstract][Full Text] [Related]
16. AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis.
Johnson JS; Gentzsch M; Zhang L; Ribeiro CM; Kantor B; Kafri T; Pickles RJ; Samulski RJ
PLoS Pathog; 2011 May; 7(5):e1002053. PubMed ID: 21625534
[TBL] [Abstract][Full Text] [Related]
17. A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function.
Ramachandran S; Osterhaus SR; Karp PH; Welsh MJ; McCray PB
Am J Respir Cell Mol Biol; 2014 Sep; 51(3):354-62. PubMed ID: 24669817
[TBL] [Abstract][Full Text] [Related]
18. A truncated CFTR protein rescues endogenous DeltaF508-CFTR and corrects chloride transport in mice.
Cormet-Boyaka E; Hong JS; Berdiev BK; Fortenberry JA; Rennolds J; Clancy JP; Benos DJ; Boyaka PN; Sorscher EJ
FASEB J; 2009 Nov; 23(11):3743-51. PubMed ID: 19620404
[TBL] [Abstract][Full Text] [Related]
19. Novel pharmacological strategies to treat cystic fibrosis.
Hanrahan JW; Sampson HM; Thomas DY
Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
[TBL] [Abstract][Full Text] [Related]
20. The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs.
Ostedgaard LS; Meyerholz DK; Chen JH; Pezzulo AA; Karp PH; Rokhlina T; Ernst SE; Hanfland RA; Reznikov LR; Ludwig PS; Rogan MP; Davis GJ; Dohrn CL; Wohlford-Lenane C; Taft PJ; Rector MV; Hornick E; Nassar BS; Samuel M; Zhang Y; Richter SS; Uc A; Shilyansky J; Prather RS; McCray PB; Zabner J; Welsh MJ; Stoltz DA
Sci Transl Med; 2011 Mar; 3(74):74ra24. PubMed ID: 21411740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
